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OBJECTIVES: Rapid titration schedule of extended-release quetiapine fumarate
(quetiapine XR) for acute bipolar mania means an effective dose can be reached by
Day 2 (versus Day 5 with quetiapine immediate release [IR]). This study evaluates
the impact of quetiapine XR on length of hospitalisation in patients with acute
bipolar mania, compared with quetiapine IR, using Thomson Reuters MarketScan®
Hospital Drug Database data. METHODS: Inpatient discharges with an ICD-9 diag-
nosis of acute bipolar mania (296.0x, 296.1x, 296.4x or 296.6x), receiving quetiapine
XR or IR, were identified. The impact of the XR formulation on length of hospitali-
sation was assessed using a generalised linear model, adjusting for patient and
hospital characteristics. Length of hospitalisation data were not normally distrib-
uted, therefore log-transformed data were included. A post hoc sensitivity analysis
evaluated length of hospitalisation (excluding an outlier quetiapine XR patient,
with a length of stay 3x higher than the second longest). RESULTS: In total, 3088
discharges between July 1, 2007 and August 31, 2010 were analysed. Modelled re-
sults showed that treatment with quetiapine XR reduced the length of hospitalisa-
tion by 6.7% compared with IR (p0.11), which corresponds to 0.6 fewer days in
hospital (6.7% of 9.6 days), based on least squares mean estimations of length of
hospitalisation in patients treated with quetiapine IR. With the outlier excluded,
quetiapine XR significantly reduced the length of hospitalisation by 9.6% compared
with IR (p0.02), corresponding to 0.9 days (9.6% of 9.6 days). CONCLUSIONS: In-
patient use of quetiapine XR in patients with acute bipolar mania may be associ-
ated with reduced length of hospitalisation, possibly due to the faster titration
schedule for quetiapine XR versus IR. Given the high costs associated with hospi-
talisation, a reduction in length of stay of approximately 7 to 10% could represent a
non-trivial cost reduction and potential savings.
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OBJECTIVES: Between 2003 and 2009, psychostimulant prescriptions in Germany
increased 2.75-fold. During the same period, administrative prevalence of ADHD in
Nordbaden/Germany grew from 0.53% (overall; age group 6-12 years, 4.74%; age
13-17 years, 1.73%, in 2003) to 0.95% (overall; 8.02% and 4.21%, respectively, in 2009).
In our earlier analyses for year 2003, we did not identify overprescribing. The pres-
ent analysis revisits the use of medication in children and adolescents with ADHD
in light of its recent increase. METHODS: The complete claims database of the
organization of physicians registered with statutory health insurance [SHI] (Kas-
senaerztliche Vereinigung, KV) in Nordbaden/Germany was available for analysis,
covering the total regional population enrolled in SHI (2.2 million). Data were
available for calendar years 2003 to 2009 and were combined with prescription data
from the SHI in order to create a patient-centered database enabling health care
utilization research. RESULTS: During the observation period, the use of medica-
tion among patients diagnosed with ADHD (in Germany, methylphenidate and
atomoxetine) increased continuously in children age 6 to 12 years, from 32.5%
(2003) over 35.3% (2006) and 40.9% (2009), whereas the increase flattened in adoles-
cents (45.7% in 2003; 53.9% in 2006, and 54.3% in 2009). Male patients and patients
with externalizing comorbidities, in particular conduct disorder, were more likely
to receive medication (peak among male adolescents with hyperkinetic conduct
disorder: 56.9% in 2003; 60.0% in 2006; 59.5% in 2009). The nonstimulant, atomox-
etine, was prescribed rarely (overall, 3.1%versus 38.2% of patients with ADHD), but
used more often in adolescents with externalizing comorbidity (up to 9.7% in male
adolescents, 2009). Compared to these numbers, only few control patients without
a diagnosis of ADHD (total number, 29) received psychostimulants in 2009.
CONCLUSIONS: Although medication use grew faster than the number of cases
diagnosed with ADHD, our data provide no evidence of overprescribing.
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ANXIOLYTICS IN PRIMARY HEALTH CARE
Guadalajara-Olmeda N, De la Poza-Plaza E, Barrachina-Martínez I, Vivas-Consuelo D
Universitat Politècnica de València, Valencia, Valencia, Spain
OBJECTIVES: Study the prescription of anxiolytics in Primary Health Care mea-
sured by the number of daily doses prescribed (DDD) to each patient (adjusting for
age and gender) in order to quantify the pharmaceutical expenditure of anxiolytics.
METHODS: Descriptive analysis of the anxiolytics prescribed during 2010 at four
districts of Primary Health Care, with an assigned population of 747,566. Population
was classified in four groups attending to the DDD prescribed: non-consumers (0
DDD), incidental consumers (1-30DDD); regular consumers (31-180DDD); long term
users (180DDD). Then, these groups were arranged by age and gender. Finally
regression analysis was applied, where the pharmaceutical expenditure in Primary
Health Care was explained through the gender. RESULTS: The 14% of the total
population were users of anxiolytics. It was observed a higher expenditure of wom-
en’s than men. Also the expenditure increases significantly with the age and also
by groups of DDD prescribed. The group of incidental consumers shows the greater
difference at age 15-55 years. In particular, women consumed 1.64 times more than
men. In the group of regular consumers, the greater difference is shown at the age
30-66 years (women consumed 1.86 times than men). The long term consumer
group shows a greater difference at the age 45-77. (Women consumed 2.5 times
more than men). Two models of regression were obtained (male/female). The mod-
els confirmed the previous results, and let us quantified the expenditure by age and
gender. CONCLUSIONS: The study shows the difference of pharmaceutical expen-
diture of anxiolytics by gender and age in Primary Health Care. It is important to
analyze the causes (physical conditions and also psychological and labor condi-
tions or a combination of them) in order to provide public health recommendations
to the National Health System.
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OBJECTIVES: Substitution therapy is commonly used across the world for the treat-
ment of opioid dependence (OD), yet little evidence exists examining country-
specific differences between acceptance and effectiveness of this treatment. The
purpose of this study was to examine differences between physician experiences
and attitudes regarding substitution therapy among a sample of OD treatment
providers in Germany and Italy. METHODS: A telephonic survey, initiated by the
Italian Federation of Operators of Dependences Departments and Services, exam-
ining opioid substitution therapy among treating physicians was administered
across two countries: Germany (n152) and Italy (n100). RESULTS: German phy-
sicians treated more than 3 times as many patients than Italian physicians (808.09
vs. 237.16; t  9.79, p  0.05), but Italian physicians treated twice as many with
substitution therapy (10.91 vs. 5.00; t  -7.53, p  0.0001). Italian physicians placed
more importance on a number of key factors when deciding to treat patients with
substitution therapy, including substitution treatment history, patient medication
requests, OD severity, and drug-drug interaction profile of the treatment medica-
tion (p’s  0.05). Italian physicians are more satisfied with treatment options (7.81
vs. 5.88; t  -6.70, p  0.0001) and believe their patients feel more satisfied with
these options (7.86 vs. 5.73; t  -8.01, p  0.0001) than their German counterparts.
Finally, Italian physicians feel that municipal drug policies facilitate patient entry
into substitution therapy (2.48 vs. 2.99; t  3.83, p  0.001) and that these policies
make physicians more willing to treat patients with substitution therapy (2.67 vs.
3.51; t  5.91, p  0.0001). CONCLUSIONS: There are key differences in physician
attitudes and experiences regarding substitution therapy across EU countries, sug-
gesting that the diversity in health care policies across countries may explain the
greater satisfaction of Italian physicians to use substitution therapy.
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OBJECTIVES: To describe the patterns and determinants of sickness absence (SA)
among users of antidepressants in the Danish working population. METHODS:
Persons starting antidepressant use in 2004 or 2005, aged 18-64 years and in the
workforce during the week prior to the first antidepressant prescription (index
prescription, IP) were identified from a representative 25% sample of the Danish
population by linking Danish national registries. Only SA 2 weeks are centrally
registered in Denmark and could be assessed. Time-to-event and Cox regression
analyses were performed to identify predictors of SA during the year following the
IP, based on previous history of SA and clinical and socio-demographic baseline
characteristics. RESULTS: The cohort comprised 26,741 persons (59.6% women).
The prevalence of SA increased from 36.0% during the year prior to 46.6% in the
year after the IP. The mean duration of first SA episodes after the IP was 19.7 weeks
(SD17.6); 68.5% of individuals on SA received cumulative SA payments for 8
weeks and 34.7% for26 weeks. The incidence of SA increased from approximately
6 months prior to the IP, and peaked during the week after, affecting 30% of the
individuals during this period. Almost 70% of persons with a SA in the year before
the IP were on SA during the first week afterwards compared to 10% of those
without previous SA. SA at any time during the year prior to the IP increased the
risk of SA by up to 3-fold. Clinical and socio-demographic baseline characteristics
were only modest predictors of SA after the IP. CONCLUSIONS: SA was prevalent in
persons starting a new episode of antidepressant use, with SA often lasting longer
than 8 weeks. Previous SA was the strongest predictor of subsequent SA in this
study.
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OBJECTIVES: There is a paucity of literature examining pharmaceutical care in
bipolar patients in India. This study examined prescribing patterns and associated
pharmaceutical care among bipolar disorder patients in a South Indian Psychiatric
Hospital. METHODS: A prospective observational study was carried out in patients
with bipolar disorder in a mental health specialty hospital in Udupi, india. The
patients were identified by medical case record reviews during study period. From
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